Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| microglial cell | 14 studies | 60% ± 18% | |
| glutamatergic neuron | 11 studies | 44% ± 22% | |
| neuron | 5 studies | 51% ± 21% | |
| GABAergic neuron | 5 studies | 31% ± 7% | |
| endothelial cell | 4 studies | 28% ± 10% | |
| astrocyte | 3 studies | 35% ± 22% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 10 studies | 31% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 95% | 1281.48 | 2518 / 2642 | 77% | 6.30 | 542 / 705 |
| prostate | 47% | 107.20 | 115 / 245 | 89% | 6.38 | 446 / 502 |
| stomach | 67% | 163.06 | 241 / 359 | 7% | 1.51 | 20 / 286 |
| spleen | 69% | 204.59 | 167 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 49% | 7.01 | 22 / 45 |
| breast | 29% | 85.43 | 134 / 459 | 9% | 0.52 | 104 / 1118 |
| skin | 23% | 39.81 | 418 / 1809 | 1% | 0.06 | 7 / 472 |
| bladder | 10% | 21.00 | 2 / 21 | 6% | 0.53 | 29 / 504 |
| esophagus | 8% | 15.80 | 115 / 1445 | 7% | 0.31 | 13 / 183 |
| uterus | 1% | 1.05 | 1 / 170 | 14% | 1.01 | 63 / 459 |
| adrenal gland | 0% | 0.59 | 1 / 258 | 13% | 1.01 | 29 / 230 |
| thymus | 0% | 0.34 | 2 / 653 | 9% | 0.47 | 55 / 605 |
| lung | 0% | 0 | 0 / 578 | 8% | 0.67 | 96 / 1155 |
| liver | 0% | 0 | 0 / 226 | 7% | 1.55 | 29 / 406 |
| intestine | 0% | 0.37 | 3 / 966 | 6% | 0.61 | 33 / 527 |
| pancreas | 0% | 0 | 0 / 328 | 4% | 0.39 | 8 / 178 |
| kidney | 0% | 0 | 0 / 89 | 4% | 0.22 | 35 / 901 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.08 | 2 / 80 |
| ovary | 0% | 0 | 0 / 180 | 2% | 0.09 | 9 / 430 |
| adipose | 0% | 0.74 | 5 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.14 | 1 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 0.19 | 1 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0015012 | Biological process | heparan sulfate proteoglycan biosynthetic process |
| GO_0030201 | Biological process | heparan sulfate proteoglycan metabolic process |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0008467 | Molecular function | [heparan sulfate]-glucosamine 3-sulfotransferase 1 activity |
| Gene name | HS3ST4 |
| Protein name | Sulfotransferase (EC 2.8.2.-) Heparan sulfate glucosamine 3-O-sulfotransferase 4 (EC 2.8.2.23) (Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 4) (3-OST-4) (Heparan sulfate 3-O-sulfotransferase 4) (h3-OST-4) |
| Synonyms | 3OST4 |
| Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to an N-unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan sulfate. Unlike 3-OST-1, does not convert non-anticoagulant heparan sulfate to anticoagulant heparan sulfate (By similarity). . |
| Accessions | Q9Y661 A5H458 ENST00000331351.6 |
